Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lamotrigine + olanzapine is a combination therapy used primarily for the treatment of bipolar disorder. Lamotrigine is an antiepileptic agent that is also effective in treating bipolar depression, while olanzapine is an atypical antipsychotic that helps manage manic or mixed episodes. When used together, these medications can provide complementary effects for patients with bipolar disorder, though they have a minor pharmacokinetic interaction where olanzapine may moderately decrease lamotrigine plasma concentrations (by approximately 24%). This combination is generally well-tolerated, with the most common adverse events being fatigue, dizziness, and mild transaminase elevations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lamotrigine + olanzapine.